Investor FAQs
Lisata Therapeutics is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. Lisata’s lead investigational product candidate, LSTA1 (formerly known as CEND-1), is designed to modify the tumor microenvironment by activating a novel uptake pathway that allows anti-cancer drugs to penetrate solid tumors more effectively. LSTA1 actuates an active transport system in a tumor-specific manner, resulting in systemically co-administered anti-cancer drugs more efficiently penetrating and accumulating in the tumor, while normal tissues are not affected. LSTA1 has demonstrated favorable safety, tolerability, and activity in clinical trials to enhance delivery of standard-of-care chemotherapy for pancreatic cancer. Lisata and its collaborators have also amassed significant non-clinical data demonstrating enhanced delivery of a range of emerging anti-cancer therapies, including immunotherapies and RNA-based therapeutics. Lisata is exploring the potential of LSTA1 to enable a variety of treatment modalities to treat a range of solid tumors more effectively. In addition, Lisata also has clinical development programs based on its autologous CD34+ cell therapy technology platform.
Ticker Symbol: LSTA
CUSIP: 128058302
Second Floor
Basking Ridge, NJ 07920
Tel: (908) 842-0100
Vice President
Investor Relations & Corporate Communications
Phone: +1-908-842-0084
Email: jmenditto@lisata.com
The Company’s corporate legal counsel is Mintz Levin Cohn Ferris Glovsky and Popeo PC (www.mintz.com).
Customer service representatives are available 8 a.m. to 8 p.m. Eastern Time, Monday through Friday.
Lisata Therapeutics, Inc.
c/o AST
6201 15th Avenue
Brooklyn, NY 11219
If your shares are registered directly in your name with the Company’s registrar and transfer agent, American Stock Transfer & Trust Company, LLC, you are considered a stockholder of record with respect to those shares. If your shares are held in a brokerage account or bank, trust, or other nominee, you are considered the “beneficial owner” of those shares.
If you are a stockholder of record, your record holder account is registered at American Stock Transfer & Trust Company, LLC (“AST”), our registrar and transfer agent.
You may contact AST by phone, by visiting their website or by mail with specific questions about your stock ownership:
You may reach an AST representative by dialing (1-800) 937-5449 or by dialing (718) 921-8124. You can also e-mail AST at help@astfinancial.com.
Customer service representatives are available 8 a.m. to 8 p.m. Eastern Time, Monday through Friday.
To contact AST via postal mail:
Lisata Therapeutics, Inc.
c/o AST
6201 15th Avenue
Brooklyn, NY 11219
Be sure to keep your account at AST current. Abandoned property laws in the United States require you to keep your account information current to avoid shares and/or funds from being turned over to the state of your last known residence. Lisata Therapeutics, Inc. is required to follow these abandoned property regulations. Even if you haven’t moved and your statements are delivered quarterly, according to some states, your account could be deemed abandoned if you have not accessed your account or contacted AST within three years.
To avoid your account being deemed abandoned or lost:
Keep your account current. Access your account on-line or vote your proxy. Ensure that AST has your correct address on file. You can change your mailing address at any time by logging on to your online account at https://www.astfinancial.com/. Please note, if you reside outside the U.S., your shares and/or funds would be turned over to Delaware, our state of incorporation.
If your shares are turned over to the state, it will be necessary to contact the state directly and file a claim, which can be a lengthy process.
If you are a beneficial owner of shares (e.g., you own shares through a bank or brokerage account) and have specific questions about your stock ownership, it will be necessary to contact your bank/broker directly for assistance.